CCRM

What CCRM does

CCRM (Centre for Commercialization of Regenerative Medicine) is a Canadian not-for-profit organization founded in 2011 and headquartered at the MaRS Centre in Toronto. It operates as an integrated commercialization platform for regenerative medicine and cell and gene therapies, addressing bottlenecks that prevent academic discoveries from reaching clinical and commercial scale. The organization bundles four interlocking offerings: CGT Manufacturing services through its wholly-owned CDMO subsidiary OmniaBio Inc. (which operates a $145M, 100,000+ sq. ft. facility at McMaster Innovation Park in Hamilton with 300+ scientific staff and 10 ISO Class 7/Grade B clean rooms), a Technology Development Incubation Program that creates new ventures from academic IP (Notch Therapeutics is the flagship end-to-end incubated company), Venture Investment in portfolio companies, and the DeepTech Bio Lab launched in 2025 to apply quantum computing, AI, and robotics to advanced therapy development.

The business model combines CDMO managed services (OmniaBio), licensing and royalties from incubated ventures, professional services for advanced therapy developers, and ongoing lab contracts to portfolio companies. CCRM serves academic researchers, biotech and pharma companies, and advanced therapy developers across more than 200 institutional partners and a global hub network spanning Toronto (CCRM), Mölndal (CCRM Nordic), Melbourne (CCRM Australia), and a planned fourth hub in Ireland supported by a Government of Ireland MOU. The organization has produced 18 portfolio companies with two exits and over CA$1.2B raised by those companies to date. Strategic capital comes from the Ontario government's $580M commitment to OmniaBio and from corporate investors such as IonQ, with whom CCRM is collaborating on quantum-AI applications for bioprocess optimization.

Name

CCRM

Legal name

Centre for Commercialization of Regenerative Medicine

Website

https://ccrm.ca

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

CCRM is a Canadian not-for-profit commercialization platform for regenerative medicine and cell and gene therapies, operating GMP manufacturing through its OmniaBio CDMO subsidiary, an academic-to-venture incubation program, and global hubs in Canada, Sweden, and Australia serving biotech, pharma, and academic clients.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy CDMO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• Cell therapy manufacturing
• Gene therapy CDMO
• Regenerative medicine commercialization
• GMP manufacturing services
• Biotech venture incubation

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. CDMO Services (OmniaBio): Contract development and manufacturing organization services for cell and gene therapies through subsidiary OmniaBio, including GMP manufacturing, process development, and commercial-scale production
2. Technology Incubation and Licensing: Internal company creation and technology licensing through incubation program, bundling IP from academic institutions and launching new ventures
3. Professional Services: Consulting, commercialization support, and expertise services for advanced therapy development
4. Lab Contract Services: Ongoing laboratory services provided to incubated and graduated companies

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

CCRM is a not-for-profit commercialization catalyst for regenerative medicine and cell/gene therapies, offering an integrated platform that bundles technology sourcing from academic labs, IP licensing, company incubation, venture investment, and GMP manufacturing services. Its wholly-owned CDMO subsidiary OmniaBio delivers commercial-scale cell and gene therapy manufacturing at a $145M+ facility in Hamilton, Ontario, while the Centre for Cell and Vector Production (CCVP) in Toronto supports Phase I and II clinical trial production across 10 ISO Class 7 clean rooms.

Product overview

CCRM operates as a catalyst for commercializing regenerative medicine technologies and cell and gene therapies. The organization offers an integrated commercialization model comprising CGT Manufacturing services, a Technology Development Incubation Program, Venture Investment, and specialized infrastructure including the Centre for Cell and Vector Production (CCVP). Through its DeepTech Bio Lab, CCRM applies quantum, AI, and robotics to life science applications. The company's CDMO subsidiary OmniaBio provides commercial-scale manufacturing capacity. Together, these offerings enable product development through translational platforms that address key bottlenecks in regenerative medicine commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• DeepTech Bio Lab™: A unique workspace leveraging data and testing technologies that apply deep tech (quantum, AI, robotics) to life science applications, particularly cell and gene therapies.
• CCRM Foundation

Products and services

• CGT Manufacturing Services End-to-end cell and gene therapy manufacturing services covering process development, GMP production, technology transfer, and specialized infrastructure for advanced therapy developers, biotech, and pharma companies.
• Technology Development Incubation Program Incubation program that transforms academic regenerative medicine and cell/gene therapy discoveries into market-ready ventures by bundling IP from academic institutions, generating proof-of-concept data, and launching companies. Has produced 18 portfolio companies with 2 exits and CA$1.2B+ raised to date.
• Venture Investment Investment services that provide capital, infrastructure access, and strategic expertise to support growth of advanced therapy companies developing cell and gene therapies.
• DeepTech Bio Lab A specialized workspace leveraging data and testing technologies that apply deep tech including quantum computing, artificial intelligence, and robotics to life science applications, particularly cell and gene therapy discovery and manufacturing.
• Centre for Cell and Vector Production (CCVP) A 20,000 sq. ft. GMP-compliant facility with 10 ISO Class 7/Grade B clean rooms for producing cells and viral vectors for Phase I and II clinical trials, operated in partnership with University Health Network.
• OmniaBio CDMO Services Contract Development and Manufacturing Organization (CDMO) services provided through wholly-owned subsidiary OmniaBio Inc., delivering commercial-scale cell and gene therapy manufacturing from a $145M+ facility at McMaster Innovation Park with 100,000 sq. ft. of manufacturing space.
• Venture by Design A venture development service that supports the creation and scaling of companies operating at the interface between academia and industry in regenerative medicine and cell/gene therapy.

Quantifiable outcome

• Portfolio companies have raised >CA$1.2B to date
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered major, strategic, core, minor and regional.

• AvectasmajorStrategic or Co-development Partner · 15 June 2026Agreement with CCRM and OmniaBio to evaluate Avectas' automated, integrated and scalable cell therapy manufacturing platform. Partnership aims to improve automation, scalability and manufacturing efficiency to address key challenges limiting patient access to cell and gene therapies.
• Government of IrelandstrategicOthers · 15 June 2026Government MOU between Ireland and Canada supporting establishment of CCRM Ireland and expanded life science collaboration.
• IonQcoreTechnology or Integration · 1 December 2025Strategic collaboration and investment partnership to develop advanced therapeutics using hybrid quantum and quantum-AI technologies. Focus areas include bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy manufacturing. Initial projects planned for Canada and Sweden in 2026.
• AfryminorImplementation/ SI/ Consulting Partner · 16 April 2025Engineering partner for CCRM Nordic's Mölndal facility development in Sweden.
• PHC Holdings CorporationmajorStrategic or Co-development Partner · 10 February 2025Partnership to advance cell and gene therapy manufacturing through development of primary T-cell expansion culture processes.
• SCTbioregionalStrategic or Co-development Partner · 22 January 2025Partnership between SCTbio and CCRM Nordic to advance cell and gene therapy development and production in Europe.
• Somite TherapeuticsmajorStrategic or Co-development Partner · 1 October 2024Collaboration to advance cell therapy flagship program through OmniaBio's manufacturing capabilities.
• Medicine by DesigncoreStrategic or Co-development Partner · 11 December 2023Alliance to bolster Canada's leading position in regenerative medicine, combining CCRM's commercialization expertise with Medicine by Design's research capabilities.
• Catamaran BiomajorStrategic or Co-development Partner · 14 March 2023Partnership with OmniaBio to advance allogeneic CAR-NK cell therapies using CCRM's manufacturing infrastructure.
• MicrofluidXminorStrategic or Co-development Partner · 11 January 2023Partnership on end-to-end bioprocessing of CAR-T cell therapies.
• MembiominorStrategic or Co-development Partner · 9 January 2023Partnership to develop single-use bioreactor to streamline viral vector production for cell and gene therapies.
• AvectasmajorStrategic or Co-development Partner · 29 November 2022Expanded collaboration between Avectas, CCRM and OmniaBio Inc. for cell therapy manufacturing platform development.
• Resolution TherapeuticsminorStrategic or Co-development Partner · 11 November 2022Research collaboration agreement with Resolution Therapeutics.
• MedipostmajorStrategic or Co-development Partner · 7 June 2022OmniaBio and Medipost acquisition and investment deal for CARTISTEM development and commercialization.
• University Health NetworkcoreStrategic or Co-development PartnerPartner in building the Centre for Cell and Vector Production (CCVP) GMP facility for producing cells and viral vectors for clinical trials.
• Founding Institutional MemberscoreStrategic or Co-development PartnerNetwork of founding institutional members supporting CCRM's mission and providing ongoing academic and research partnerships.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Lonza: Global leader in contract development and manufacturing for biologics and cell & gene therapies, with significant GMP viral vector and cell therapy capacity. Directly competes with CCRM/OmniaBio for advanced therapy manufacturing contracts at a much larger scale.
• Catalent: Major CDMO with dedicated cell and gene therapy services including viral vector and plasmid manufacturing. Competes with CCRM for commercial and clinical-stage CGT manufacturing programs across North America and Europe.
• Thermo Fisher Scientific (Patheon): Pharma services division offering biologics and cell/gene therapy CDMO capabilities through Patheon and viral vector manufacturing. A broad incumbent competing with CCRM/OmniaBio on integrated development and manufacturing offerings.
• WuXi Advanced Therapies: Cell and gene therapy CDMO arm of WuXi AppTec offering viral vector, cell therapy, and plasmid manufacturing. A broad incumbent competing with CCRM globally across CGT development and manufacturing.

Direct peers

• Forge Biologics: US-based hybrid CDMO and gene therapy development company focused on AAV viral vector manufacturing and gene therapy services. Closely comparable to CCRM/OmniaBio as a specialized CGT CDMO with platform-level integration.
• Andelyn Biosciences: AAV and gene therapy CDMO spun out of Nationwide Children's Hospital with GMP viral vector manufacturing capacity. Comparable to CCRM's CCVP and OmniaBio capabilities in clinical and commercial gene therapy manufacturing.
• Viralgen Vector Core (AskBio): AAV-focused CDMO with commercial-scale viral vector manufacturing based in Spain. Directly comparable to CCRM/OmniaBio's gene therapy manufacturing capacity for clinical and commercial supply.
• AGC Biologics: Global biologics CDMO with cell and gene therapy services including viral vector and cell therapy manufacturing. Comparable in service scope and clinical/commercial focus to CCRM/OmniaBio.

Emerging players

• ElevateBio: Cell and gene therapy company combining in-house therapeutic development with BaseCamp CDMO capabilities. Comparable to CCRM in integrating incubation/venture creation with CGT manufacturing, though structured as a for-profit.
• Cellares: Emerging cell therapy manufacturing technology company developing automated, high-throughput cell therapy manufacturing platforms. Adjacent peer relevant to CCRM through the Avectas automation partnership and DeepTech Bio Lab robotics focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ccrm_ca
• Facebookfacebook.com/commercializinglivingtherapies
• LinkedInlinkedin.com/company/centre-for-commercialization-of-regenerative-medicine-ccrm-
• Instagraminstagram.com/ccrm_ca

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CCRM